CGTX Company Profile and Key Details

Cognition Therapeutics, Inc. (NASDAQ:CGTX) closed at $1.40 USD, losing -$0.19 (-11.95%) from the previous close of $1.59. The stock is currently mid-range between its 52-week high and low $0.22 and $3.83. With a market capitalization of about $103.02 million, Cognition Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.24). Key stats such as the average daily volume over the past year has been around 1.34 million shares, trading with heavier-than-usual volume. Headquartered in Purchase, NY, Cognition Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lisa Ricciardi, the company employs approximately 25 people and listed since October 08, 2021. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Short-term trend indicators are mixed aligned (SMA20 -2.24%, SMA50 -3.19%, SMA200 50.97%). The stock’s 14-day RSI is 49.0 (neutral), while the ATR of 0.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -58.49% below its high and over 615.25% above its low. Average 10-day trading volume of 972.57 thousand shares is below the 3-month average of 1.33 million, indicating normal recent market interest.

Cognition Therapeutics, Inc. has 88.27 million shares outstanding. The public float is 81.77 million shares, elevated short interest at 8.95% of float. This equals 7.34 million shares. The short ratio is 6.05 days. Institutional investors hold 12.83% of the float. Insiders own 0.7%. Ogden CAP Associates, LLC holds 2.21 million shares, Golden Seeds Cognition Therapeutics LLC has 2.18 million shares and Breedlove Mark H. has 404.44 thousand shares.

Cognition Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Cognition Therapeutics, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -16.44%. Wall Street analysts project EPS growth of 20.63% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$18.06. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $3.00. The high target offers 591.82% upside. The low target suggests 88.68% downside. The mean target is $5.00. This offers 214.47% upside. Cognition Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -14.29%. The prior quarter beat by -8.33%. Over the last six quarters, Apple has recorded several small beats. These include -99.92% in August 08, 2024.

Cognition Therapeutics, Inc. trades at a P/E ratio of -2.79, slightly below the S&P 500 average, with a price-to-sales ratio of 425.31 and a price-to-book ratio of 13.09 reflecting a rich premium to book value. The P/FCF stands at -3.46, also above market averages. Compared to sector medians, Cognition Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) shares are up 126.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cognition Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.88, suggesting 395.6% upside. Our AI forecast model points to short-term weakness (-1.89% over two weeks), a medium-term rise (50.31% over three months), and a longer-term gain (788.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cognition Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.89%, with price expected at $1.56 by January 05, 2026, within a range of $1.44 to $1.70 3-Month Outlook: Projected rise of 50.31%, reaching $2.39 by March 20, 2026, with a range of $2.34 to $2.46. 1-Year Outlook: Projected gain of 788.68%, with price at $14.13 by December 22, 2026, within a range of $14.06 to $14.26.